{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T18:01:25Z","timestamp":1791396085074,"version":"4.3.3"},"reference-count":29,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1016\/j.exphem.2010.09.008","type":"journal-article","created":{"date-parts":[[2010,10,2]],"date-time":"2010-10-02T08:41:49Z","timestamp":1286008909000},"page":"95-101","source":"Crossref","is-referenced-by-count":34,"title":["Disease burden at the progenitor level is a feature of primary myelofibrosis: a multivariable analysis of 164 JAK2 V617F-positive myeloproliferative neoplasm patients"],"prefix":"10.1016","volume":"39","author":[{"given":"Brady L.","family":"Stein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna M.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ophelia","family":"Rogers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Ann","family":"Isaacs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry L.","family":"Spivak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison R.","family":"Moliterno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2010.09.008_bib1","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/leu.2008.113","article-title":"Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal","volume":"22","author":"Vannucchi","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2010.09.008_bib2","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1056\/NEJM197610212951702","article-title":"Polycythemia vera: stem-cell and probable clonal origin of the disease","volume":"295","author":"Adamson","year":"1976","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2010.09.008_bib3","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/j.1365-2141.1995.tb03391.x","article-title":"Clonal analysis of haemopoietic cells in essential thrombocythaemia","volume":"90","author":"el Kassar","year":"1995","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2010.09.008_bib4","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/(SICI)1096-8652(199902)60:2<158::AID-AJH14>3.0.CO;2-9","article-title":"Heterogeneity of clonal development in chronic myeloproliferative disorders","volume":"60","author":"Ferraris","year":"1999","journal-title":"Am J Hematol"},{"key":"10.1016\/j.exphem.2010.09.008_bib5","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1182\/blood-2005-03-1240","article-title":"The kinetics of clonal dominance in myeloproliferative disorders","volume":"106","author":"Catlin","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2010.09.008_bib6","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/j.exphem.2008.05.006","article-title":"Phenotypic variability within the JAK2 V617F-positive MPD: roles of progenitor cell and neutrophil allele burdens","volume":"36","author":"Moliterno","year":"2008","journal-title":"Exp Hematol"},{"key":"10.1016\/j.exphem.2010.09.008_bib7","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.3324\/haematol.2009.014407","article-title":"Sex differences in the JAK2V617F allele burden in the chronic myeloproliferative disorders","volume":"95","author":"Stein","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.exphem.2010.09.008_bib8","first-page":"132","article-title":"Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols","volume":"23","author":"Berk","year":"1986","journal-title":"Semin Hematol"},{"key":"10.1016\/j.exphem.2010.09.008_bib9","first-page":"29","article-title":"Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment","volume":"34","author":"Murphy","year":"1997","journal-title":"Semin Hematol"},{"key":"10.1016\/j.exphem.2010.09.008_bib10","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1200\/JCO.1999.17.9.2954","article-title":"Myelofibrosis with myeloid metaplasia: diagnostic definition and prognostic classification for clinical studies and treatment guidelines","volume":"17","author":"Barosi","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2010.09.008_bib11","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.leukres.2006.12.002","article-title":"Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT)","volume":"31","author":"Mesa","year":"2007","journal-title":"Leuk Res"},{"key":"10.1016\/j.exphem.2010.09.008_bib12","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1056\/NEJMc051878","article-title":"JAK2 mutations in myeloproliferative disorders","volume":"353","author":"Tefferi","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2010.09.008_bib13","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1179\/102453309X385188","article-title":"Limited efficacy of hydroxyurea in lowering of the JAK2 V617F allele burden","volume":"14","author":"Larsen","year":"2009","journal-title":"Hematology"},{"key":"10.1016\/j.exphem.2010.09.008_bib14","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/j.1365-2141.2009.07597.x","article-title":"The production of JAK2 wild-type platelets is not downregulated in patients with JAK2 V617F mutant-positive essential thrombocythaemia","volume":"145","author":"Lambert","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2010.09.008_bib15","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1182\/blood-2006-10-054940","article-title":"The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera","volume":"110","author":"Dupont","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2010.09.008_bib16","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.1182\/blood-2007-09-111971","article-title":"Clonal heterogeneity in polycythemia vera patients with JAK2 exon12 and JAK2-V617F mutations","volume":"111","author":"Li","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2010.09.008_bib17","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1182\/blood-2008-02-137877","article-title":"The hematopoietic stem cell compartment of JAK2V617F-positive myeloproliferative disorders is a reflection of disease heterogeneity","volume":"112","author":"James","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2010.09.008_bib18","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1001\/jama.2010.853","article-title":"Primary myelofibrosis and the myeloproliferative neoplasms: the role of individual variation","volume":"303","author":"Stein","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.exphem.2010.09.008_bib19","doi-asserted-by":"crossref","first-page":"666","DOI":"10.3324\/haematol.2009.013623","article-title":"High-resolution single-nucleotide polymorphism array-profiling in myeloproliferative neoplasms identifies novel genomic aberrations","volume":"95","author":"Stegelmann","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.exphem.2010.09.008_bib20","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1182\/blood-2009-08-236596","article-title":"Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm","volume":"115","author":"Beer","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2010.09.008_bib21","doi-asserted-by":"crossref","first-page":"3676","DOI":"10.1182\/blood-2005-09-3826","article-title":"Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders","volume":"107","author":"Passamonti","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2010.09.008_bib22","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1182\/blood-2009-12-259747","article-title":"JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia","volume":"116","author":"Li","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2010.09.008_bib23","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1182\/blood-2010-06-287318","article-title":"JAK2 impairs stem cell function?","volume":"116","author":"Skoda","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2010.09.008_bib24","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1038\/leu.2008.357","article-title":"Molecular profile of CD34+ stem\/progenitor cells according to JAK2V617F mutation status in essential thrombocythemia","volume":"23","author":"Catani","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2010.09.008_bib25","doi-asserted-by":"crossref","first-page":"4339","DOI":"10.1158\/1078-0432.CCR-10-1092","article-title":"Transcriptional profiling of polycythemia vera identifies gene expression patterns both dependent and independent from the action of JAK2V617F","volume":"16","author":"Berkofsky-Fessler","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.exphem.2010.09.008_bib26","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.ccr.2010.05.015","article-title":"Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells","volume":"17","author":"Mullally","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.exphem.2010.09.008_bib27","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1038\/leu.2009.141","article-title":"Mutations of ASXL1 gene in myeloproliferative neoplasms","volume":"23","author":"Carbuccia","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2010.09.008_bib28","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1182\/blood-2010-02-270108","article-title":"Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms","volume":"116","author":"Oh","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2010.09.008_bib29","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1038\/leu.2010.69","article-title":"Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1","volume":"24","author":"Tefferi","year":"2010","journal-title":"Leukemia"}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X10004881?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X10004881?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,5]],"date-time":"2019-06-05T05:29:21Z","timestamp":1559712561000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X10004881"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["S0301472X10004881"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2010.09.008","relation":{},"ISSN":["0301-472X"],"issn-type":[{"value":"0301-472X","type":"print"}],"subject":[],"published":{"date-parts":[[2011,1]]}}}